Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting
Major improvements have been made in the treatment of myeloma. However, all patients, perhaps with some exceptions, eventually relapse, even after autologous stem cell transplantation (ASCT). In that setting, the combinations of new drugs, namely the IMiDs and the proteasome inhibitors along with st...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Leukemia and lymphoma
Year: 2016, Volume: 58, Issue: 4, Pages: 797-808 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428194.2016.1228926 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1080/10428194.2016.1228926 Verlag, Volltext: https://doi.org/10.1080/10428194.2016.1228926 
|
| Author Notes: | Laurent Garderet, Gordon Cook, Holger W. Auner, Benedetto Bruno, Henk Lokhorst, Jose Antonio Perez-Simon, Firoozeh Sahebi, Christof Scheid, Curly Morris, Anja van Biezen, Mohamad Sobh, Mauricette Michallet, Gösta Gahrton, Stefan Schönland, Nicolaus Kröger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576738469 | ||
| 003 | DE-627 | ||
| 005 | 20220814171710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180621r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2016.1228926 |2 doi | |
| 035 | |a (DE-627)1576738469 | ||
| 035 | |a (DE-576)506738469 | ||
| 035 | |a (DE-599)BSZ506738469 | ||
| 035 | |a (OCoLC)1341012134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Garderet, Laurent |d 1964- |e VerfasserIn |0 (DE-588)1161564748 |0 (DE-627)1024850803 |0 (DE-576)506738337 |4 aut | |
| 245 | 1 | 0 | |a Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting |c Laurent Garderet, Gordon Cook, Holger W. Auner, Benedetto Bruno, Henk Lokhorst, Jose Antonio Perez-Simon, Firoozeh Sahebi, Christof Scheid, Curly Morris, Anja van Biezen, Mohamad Sobh, Mauricette Michallet, Gösta Gahrton, Stefan Schönland, Nicolaus Kröger |
| 264 | 1 | |c 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 21 Sep 2016 | ||
| 500 | |a Gesehen am 21.06.2018 | ||
| 520 | |a Major improvements have been made in the treatment of myeloma. However, all patients, perhaps with some exceptions, eventually relapse, even after autologous stem cell transplantation (ASCT). In that setting, the combinations of new drugs, namely the IMiDs and the proteasome inhibitors along with steroids, give encouraging results in relapsed patients. The median progression-free survival (PFS) is 20 months with lenalidomide plus dexamethasone plus ixazomib and 26 months with lenalidomide plus dexamethasone plus carfilzomib. Monoclonal antibodies have emerged as an additional new treatment option. The antibody anti-SLAMF7, elotuzumab, in combination with lenalidomide plus dexamethasone gives a median PFS of 20 months. The antibody daratumumab, targeting CD38, alone has an outstanding activity in previously heavily treated patients. Its use in combination is ongoing. Transplantation remains a major treatment option. For patients who relapse at least 18 months from the initial ASCT, a second ASCT can be performed with an expected time to progression of 19 months from the time of transplantation. For patients relapsing earlier and/or with high-risk characteristics and who are still chemosensitive, with a suitable donor, an allogeneic transplantation can be considered. The optimal treatment combination and sequence remain to be determined. | ||
| 534 | |c 2016 | ||
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a Myeloma | |
| 650 | 4 | |a allogeneic stem cell transplantation | |
| 650 | 4 | |a autologous stem cell transplantation | |
| 650 | 4 | |a immunomodulatory drugs | |
| 650 | 4 | |a proteasome inhibitors | |
| 650 | 4 | |a relapse | |
| 700 | 1 | |a Schönland, Stefan |d 1969- |e VerfasserIn |0 (DE-588)122405226 |0 (DE-627)705896137 |0 (DE-576)293255792 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 58(2017), 4, Seite 797-808 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting |
| 773 | 1 | 8 | |g volume:58 |g year:2017 |g number:4 |g pages:797-808 |g extent:10 |a Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2016.1228926 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/10428194.2016.1228926 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180621 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 122405226 |a Schönland, Stefan |m 122405226:Schönland, Stefan |d 910000 |d 910100 |e 910000PS122405226 |e 910100PS122405226 |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 999 | |a KXP-PPN1576738469 |e 3013334428 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting","title":"Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting"}],"language":["eng"],"name":{"displayForm":["Laurent Garderet, Gordon Cook, Holger W. Auner, Benedetto Bruno, Henk Lokhorst, Jose Antonio Perez-Simon, Firoozeh Sahebi, Christof Scheid, Curly Morris, Anja van Biezen, Mohamad Sobh, Mauricette Michallet, Gösta Gahrton, Stefan Schönland, Nicolaus Kröger"]},"person":[{"family":"Garderet","display":"Garderet, Laurent","given":"Laurent","role":"aut"},{"family":"Schönland","given":"Stefan","role":"aut","display":"Schönland, Stefan"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1576738469","origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}],"physDesc":[{"extent":"10 S."}],"id":{"eki":["1576738469"],"doi":["10.1080/10428194.2016.1228926"]},"relHost":[{"note":["Gesehen am 08.09.15"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["324746237"],"zdb":["2030637-4"],"issn":["1029-2403"]},"disp":"Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meetingLeukemia and lymphoma","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"324746237","origin":[{"dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedDisp":"1989-","publisherPlace":"London [u.a.] ; London [u.a.]"}],"pubHistory":["1.1989/90 -"],"language":["eng"],"part":{"extent":"10","pages":"797-808","issue":"4","volume":"58","text":"58(2017), 4, Seite 797-808","year":"2017"},"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}]}],"note":["Published online: 21 Sep 2016","Gesehen am 21.06.2018"]} | ||
| SRT | |a GARDERETLATREATMENTO2017 | ||